Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome

Myelodysplastic syndromes (MDS) are a group of clonal myeloid disorders characterized by low blood counts and a propensity to develop acute myeloid leukemia. The management of lowerrisk (LR) MDS with persistent cytopenias remains suboptimal. Eltrombopag, a thrombopoietin-receptor agonist, can improv...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Haematologica
Κύριοι συγγραφείς: Vicente, Alana, Patel, Bhavisha A., Gutierrez-Rodrigues, Fernanda, Groarke, Emma M., Giudice, Valentina, Lotter, Jennifer, Feng, Xingmin, Kajigaya, Sachiko, Weinstein, Barbara, Barranta, Evette, Olnes, Matthew J., Parikh, Ankur R., Albitar, Maher, Wu, Colin O., Shalhoub, Ruba, Calvo, Katherine R., Townsley, Danielle M., Scheinberg, Phillip, Dunbar, Cynthia E., Young, Neal S., Winkler, Thomas
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Fondazione Ferrata Storti 2020
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7716353/
https://ncbi.nlm.nih.gov/pubmed/33256377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2020.249995
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια